Rosen Law Firm Leads Securities Lawsuit Against BioAge Labs, Inc. Following Discontinued Trial

Class Action Lawsuit Notification for BioAge Labs, Inc. Investors

Investors who purchased shares of BioAge Labs, Inc. (NASDAQ: BIOA) during its initial public offering (IPO) on September 26, 2024, have the opportunity to join a class action lawsuit led by the Rosen Law Firm. This lawsuit comes in response to serious allegations related to BioAge's clinical trial results and the conduct of the company during the investor’s engagement.

Background of the Case

On January 9, 2025, the Rosen Law Firm publicly announced the filing of the class action lawsuit on behalf of investors. The core of the allegations centers around disclosures made by BioAge during the IPO, primarily about their lead product candidate, azelaprag, which was under evaluation in the ongoing STRIDES clinical trial. The firm emphasizes that prospective investors were misled regarding the safety and efficacy of azelaprag, strongly indicating no potential concerns ahead of the IPO.

Defendants representing BioAge pointed to the collaboration with Eli Lilly's Chorus clinical development organization, and a promising framework that included a second phase 2 trial combining azelaprag with semaglutide aimed at obesity treatment. They projected that topline results would achieve their endpoints in 2025, refreshing investor confidence.

Disruption of Development

However, in a sharp pivot that has shocked the investing community, BioAge discontinued the STRIDES Phase 2 clinical study when elevated liver enzyme levels were recorded among trial participants, signaling possible organ damage. This halting of trials raised significant questions about prior disclosures made by the firm, particularly as these safety issues were not raised in earlier studies, signaling potential negligence or misinformation.

As detailed in the lawsuit, this abrupt discontinuation of a pivotal trial, coupled with inadequate disclosure regarding the risk of liver transaminitis, suggests that the information presented to investors was notably absent of risk awareness. Consequently, the lawsuit asserts that the company's statements during the IPO were misleading and illegitimate.

Investor Compensation

Investors who feel they have been affected have until March 10, 2025, to register as lead plaintiffs in this class action. By doing so, they may potentially recover damages without incurring any upfront fees, as Rosen Law operates on a contingency fee basis.

The law firm encourages affected investors to take prompt action to join the suit. Those interested can learn more by visiting the Rosen Law Firm's website or contacting their office directly for additional information.

Selecting Legal Representation

Rosen Law Firm emphasizes the importance of selecting qualified counsel, showcasing their track record as a global leader in investor rights with a history of successful securities class action settlements. Notably, the firm has received recognition for recoveries amounting to hundreds of millions of dollars for its clients over the years.

For potential claimants, the firm suggests that while there’s no class yet certified, joining now can set the stage for future involvement in recovery should the class be validated by the court.

In conclusion, the situation surrounding BioAge Labs underscores the necessity for both transparency and accountability in clinical trials and initial public offerings. Investors are advised to remain vigilant and informed about their rights in such matters.